help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 10, No. 7, 508-517, August 2005; doi:10.1634/theoncologist.10-7-508
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gilbertson, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gilbertson, R. J.

ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty

Richard J. Gilbertson

Departments of Developmental Neurobiology and Hematology/Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA

Richard J. Gilbertson, M.D., Ph.D., Departments of Developmental Neurobiology and Hematology/Oncology, St. Jude Children’s Research Hospital, 332 N. Lauderdale Street, Memphis, Tennessee 38105, USA. Telephone: 901-495-3913; Fax: 901-495-2270; e-mail: Richard.Gilbertson{at}stjude.org

Adult oncologists and their research colleagues have "led the charge" in the war on cancer. Their efforts have generated effective new chemotherapies that target cancer causing molecular alterations. It is hoped that these successes will be repeated within the pediatric oncology community. Testing whether molecular targeted therapies of adult cancers are also effective against childhood cancers might allow the rapid introduction of these exciting new agents into the pediatric clinic. However, it is imperative that we do not introduce blindly these agents into the pediatric population. We must ensure that molecular targets in adult cancers also fulfill a number of important criteria within the pediatric disease. This review addresses the issues surrounding the identification of molecular targets in pediatric cancers by focusing on studies of the ERBB2 oncogene.

Key Words. ERBB2 • Medulloblastoma • Pediatric cancer • Molecular drug target




This article has been cited by other articles:


Home page
 Cancer Res.Home page
N. Ahmed, M. Ratnayake, B. Savoldo, L. Perlaky, G. Dotti, W. S. Wels, M. B. Bhattacharjee, R. J. Gilbertson, H. D. Shine, H. L. Weiss, et al.
Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells
Cancer Res., June 15, 2007; 67(12): 5957 - 5964.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 2005 by AlphaMed Press.